Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000649 · ClinicalTrials.gov registry record · Phase 2
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT01000649 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 53 participants.
The verdict
NCT01000649, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this trial was to examine the safety and tolerability, pharmacokinetics of FE 202158 and to assess whether it can stabilize blood pressure and reduce vascular (blood vessel) leakage. FE 202158 had previously been tested in healthy volunteers.
Interventions
- OTHER Placebo
- DRUG FE 202158 1.25
- DRUG FE 202158 2.5
- DRUG FE 202158 3.75
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01000649
The ClinicalTrials.gov registry entry for NCT01000649 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01000649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01000649 about?
NCT01000649 is a clinical study titled "Effects of the V1a Agonist FE 202158 in Patients With Septic Shock". The purpose of this trial was to examine the safety and tolerability, pharmacokinetics of FE 202158 and to assess whether it can stabilize blood pressure and reduce vascular (blood vessel) leakage. FE 202158 had previously been tested in healthy volunteers.
What is the current status of trial NCT01000649?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2009-11. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01000649?
The interventions under investigation include: Placebo (OTHER), FE 202158 1.25 (DRUG), FE 202158 2.5 (DRUG), FE 202158 3.75 (DRUG).
Who is sponsoring clinical trial NCT01000649?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.